文献速递炎症性肠病消化道肿瘤与早癌

JAK抑制剂在炎症性肠病及其他免疫介导疾病中的安全性:系统综述与荟萃分析

Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
PubMed 文献 · Gastroenterology · 2020-01-09

该系统综述与荟萃分析纳入82项研究、66,159例接受JAK抑制剂治疗的免疫介导疾病患者,评估不良事件发生率。结果显示带状疱疹感染风险显著增加(RR 1.57),其他不良事件及死亡率未升高,为JAK抑制剂安全性提供综合证据。

要点

  • JAK抑制剂总体不良事件发生率为42.65/100人年,严重不良事件为9.88/100人年。
  • 带状疱疹感染风险显著增加(RR 1.57,95%CI 1.04-2.37)。
  • 死亡率与安慰剂或阳性对照相比未增加(RR 0.72,95%CI 0.40-1.28)。

核心结论

  • 接受JAK抑制剂治疗的免疫介导疾病患者带状疱疹感染风险显著增加。
  • 其他不良事件及死亡率在JAK抑制剂治疗患者中未增加。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane对照试验中心注册库(1990年1月1日至2019年7月1日)并手工检索会议数据库(2012至2018年)。
  • 最终纳入82项研究,共66,159例暴露于JAK抑制剂的免疫介导疾病患者,其中三分之二为随机对照试验。
  • 纳入疾病包括类风湿关节炎、炎症性肠病、银屑病或强直性脊柱炎,评估药物包括托法替布、乌帕替尼、非戈替尼和巴瑞替尼。

主要发现

  • 不良事件发生率为42.65/100人年,严重不良事件发生率为9.88/100人年。
  • 严重感染、带状疱疹感染、恶性肿瘤和主要心血管事件发生率分别为2.81/100人年、2.67/100人年、0.89/100人年和0.48/100人年。
  • 荟萃分析显示JAK抑制剂组带状疱疹感染风险显著增加(RR 1.57,95%CI 1.04-2.37)。
  • 死亡率与安慰剂或阳性对照相比未增加(RR 0.72,95%CI 0.40-1.28)。

临床怎么用

  • 临床使用JAK抑制剂时应监测带状疱疹感染风险,尤其对于免疫介导疾病患者。
  • JAK抑制剂治疗未显示死亡率增加,但需结合患者个体情况综合评估安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Inhibitors of Janus kinases (JAKs) are being developed for treatment of inflammatory bowel diseases and other immune-mediated diseases. Tofacitinib is effective in treatment of ulcerative colitis, but there are safety concerns. We performed a systematic review and meta-analysis to investigate the safety profile of tofacitinib, upadacitinib, filgotinib, and baricitinib in patients with rheumatoid arthritis, inflammatory bowel diseases, psoriasis, or ankylosing spondylitis. METHODS: We searched the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials from January 1, 1990, through July 1, 2019. We performed a manual review of conference databases from 2012 through 2018. The primary outcome was incidence rates of adverse events (AEs) and serious AEs. We also estimated incidence rates of serious infections, herpes zoster infection, non-melanoma skin cancer, other malignancies, major cardiovascular events, venous thromboembolism, and mortality. We performed a meta-analysis, which included controlled studies, to assess the relative risk of these events. RESULTS: We identified 973 studies; of these, 82 were included in the final analysis, comprising 66,159 patients with immune-mediated diseases who were exposed to a JAK inhibitor. Two-thirds of the included studies were randomized controlled trials. The incidence rate of AEs was 42.65 per 100 person-years and of serious AEs was 9.88 per 100 person-years. Incidence rates of serious infections, herpes zoster infection, malignancy, and major cardiovascular events were 2.81 per 100 person-years, 2.67 per 100 person-years, 0.89 per 100 person-years, and 0.48 per 100 person-years, respectively. Mortality was not increased in patients treated with JAK inhibitors compared with patients given placebo or active comparator (relative risk 0.72; 95% confidence interval 0.40-1.28). The meta-analysis showed a significant increase in risk of herpes zoster infection among patients who received JAK inhibitors (relative risk 1.57; 95% confidence interval 1.04-2.37). CONCLUSIONS: In a systematic review and meta-analysis, we found an increased risk of herpes zoster infection among patients with immune-mediated diseases treated with JAK inhibitors. All other AEs were not increased among patients treated with JAK inhibitors.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. Gastroenterology. 2020. PMID: 31926171. doi:10.1053/j.gastro.2020.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。